Dr. Heinz Schwer, MBA
Chief Executive Officer
Dr. Schwer served three years as CEO of Lanthio Pharma B.V., a Dutch drug development company that was acquired by MorphoSys AG. He led the company’s effort in advancing its therapeutic program from pre-clinical into clinical stage. Before his time at Lanthio, Dr. Schwer was Senior Director at MorphoSys AG from 2010 until 2014. In this period he served as strategic technology advisor and head of “Innovation Capital”, the company’s corporate venture business. Prior to this position, he was co-founder and CEO of Sloning Biotechnology, a biotech company that became market leader in generating recombinant gene libraries for pharma and industrial biotech. Throughout his career, Dr. Schwer has been involved in numerous M&A transactions and helped to raise over EUR 40m capital through private and public offerings. Dr. Schwer received his PhD in clinical chemistry from University of Regensburg, was a postdoctoral fellow at Harvard Medical School at the Beth Israel Hospital and Dana-Faber Cancer Institute and holds an MBA from Henley Management College, UK.
Univ.-Prof. Dr. med. Dorothee von Laer
Co-founder and Scientific Advisor
Prof. von Laer is a medical doctor, an internationally accepted biomedical researcher and the inventor of the VSV-GP technology. She is a co-founder of ViraTherapeutics and a full professor and head of the Virology Institute at the Medical University of Innsbruck in Tyrol, Austria. Prof. von Laer gained biotech experience as a co-founder, shareholder and part-time Chief Scientific Officer of the Vision7 GmbH, a German biotech company founded in 2000. She served on the advisory board of the Paul-Ehrlich-Institute in Langen, which is the German drug administration for biopharmaceuticals, and is a member of the review board of the GO-Bio funding program of the German Federal Ministry for Education and Research (BMBF).